

Fact Sheet

May 2011

Investor Relations
Tel.: ++ 386 7 331 2287
Fax: ++ 386 7 332 1523
e-mail: finance@krka.biz


website: www.krka.biz



Living a healthy life.

- One of the leading generic pharmaceutical companies in the world with over 50 years of experience in the industry and strong focus on branded generic prescription pharmaceuticals (Rx).
- Extensive Rx portfolio supplemented by self-medication (OTC), animal health, cosmetic products and health & tourism services (Terme Krka).
- Serving customers in more than 70 markets.
- Headquartered in Slovenia with production & distribution facilities in Slovenia, Poland, Croatia, Russia and in Germany.

Group Net Sales & Profit in € Millions




- For 2011 Krka Group plans to achieve sales of € 1,069 million, net profit of € 162 million and investment expenditure of € 159 million.
- In 2010–2014 we are planning to achieve average annual sales growth above industry average.

Future Growth Prospects

- Focus on marketing and further development of own marketing & sales network.
- Pursuing economics of scale.
- Major patent expiries of blockbuster drugs.
- Convergence of medicines expenditure per capita towards higher, western levels on our key markets.
- Global generic market growth due to governments' health care cost saving efforts.
- Emergence of new generic markets.


Total group sales 2010 € 1,010 Million




Strategic Focus

- Prioritising European and central Asian markets.
- Prioritising the strengthening of the pharmaceutical and chemical activities.
- Strengthening the competitive advantage of the product portfolio by maintaining the highest possible share of vertical integrated products and launching selected products as the first generic on selected key markets.
- Developing generic medicines and preparing market authorisation documentation before the expiry of the product patent for the original medicine.
- Strengthening competitiveness on western European markets by establishing its own marketing companies.
- Strengthening synergy within the Krka Group (in expertise and costs).
- Restructuring the purchasing market to ensure the continual reduction of purchase prices.
- Pursuing a moderate dividend increase policy.
- Continued growth of market shares through the purchase of local pharmaceutical companies or business acquisition on selected markets.
- Maintaining our economic, social and protection responsibilities for the environment in which we operate.
- Maintaining independence.

Group sales by regions in 1Q 2011 in € Millions



Group sales by segment in 1Q 2011 in € Millions




New Product Development

- In 1Q 2011 Krka received first marketing authorisations for 8 new products in 19 pharmaceutical forms.
- In 1Q 2011 Krka acquired authorizations for galantamine for Alzheimer's disease and two new sartans – irbesartan and candesartan.
- In 2010 Krka acquired marketing authorisation for 24 new products in 49 dosage forms and strengths.
- In 2010 Krka acquired marketing authorisation for 925 products in 1,891 pharmaceutical forms and strengths in 58 countries.
- In 2010 9% of sales revenues was allocated to research and development

Share Listing

- Krka is the most liquid share with the highest market capitalization on the Ljubljana Stock Exchange.
- Share split executed on 3 September 2007 (10 shares for 1 existing).
- Market capitalisation of approximately € 2.1 Billion.

Share performance relative to comparable indices



Stock Market Data

as of 13 May 2011 (in €)

Stock Symbol:	KRKG
Recent share price:	59.35
Market Capitalization:	2.10 Billion
52 - week range:	70.13 — 57.00

Home page

<http://www.krka.biz/en/finance/>

Additional information

For additional information, contact:

Krka, d. d., Novo mesto
Finance Division
Šmarješka cesta 6
8501 Novo mesto
Slovenia

Tel: + 386 7 331 2287
Fax: + 386 7 332 1523
e-mail: finance@krka.biz